This trial is active, not recruiting.

Condition colorectal cancer
Treatments gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, immunologic technique
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date July 2007
Trial size 200 participants
Trial identifier NCT00897754, CDR0000560986, ECOG-E3200T2


RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.

PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Mean scores for VEGFb and pan-VEGF gene expression by IHC
time frame:
Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios
time frame:
Gene expression as measured by tissue microarrays
time frame:
Splice form expression as measured by reverse transcriptase-PCR
time frame:
VEGF165b protein expression as measured by ELISA
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum - Receiving bevacizumab on clinical trial E-3200 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Additional Information

Official title Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy
Description OBJECTIVES: - Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy. OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
Trial information was received from ClinicalTrials.gov and was last updated in May 2009.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).